Company Intellia Therapeutics, Inc.

Equities

NTLA

US45826J1051

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
27.51 USD +1.81% Intraday chart for Intellia Therapeutics, Inc. -0.51% -9.77%

Business Summary

Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.

Number of employees: 526

Sales per Business

USD in Million2022Weight2023Weight Delta
Genome Editing-based Therapies
100.0 %
52 100.0 % 36 100.0 % -30.40%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
52 100.0 % 36 100.0 % -30.40%

Managers

Managers TitleAgeSince
Chief Executive Officer 66 14-06-30
Director of Finance/CFO 53 18-10-28
Chief Tech/Sci/R&D Officer 67 -
Chief Tech/Sci/R&D Officer 63 19-05-27
Chief Tech/Sci/R&D Officer 69 20-04-29
Investor Relations Contact - -
- -
General Counsel - -
Corporate Officer/Principal 51 21-12-19
Human Resources Officer - -

Members of the board

Members of the board TitleAgeSince
Director/Board Member 67 19-01-23
Chief Executive Officer 66 14-06-30
Chairman 62 17-07-23
Director/Board Member 57 23-04-13
Director/Board Member 72 18-10-30
Director/Board Member 62 21-04-08
Director/Board Member 61 22-04-27

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 96,106,405 94,824,319 ( 98.67 %) 0 98.67 %

Shareholders

NameEquities%Valuation
ARK Investment Management LLC
11.87 %
11,412,449 11.87 % 367 M $
BlackRock Advisors LLC
8.835 %
8,490,522 8.835 % 273 M $
Vanguard Fiduciary Trust Co.
8.686 %
8,347,449 8.686 % 268 M $
4,735,861 4.928 % 152 M $
Nikko Asset Management Americas, Inc.
3.619 %
3,478,562 3.619 % 112 M $
Eaton Vance Management
2.648 %
2,545,022 2.648 % 82 M $
Wellington Management Co. LLP
2.556 %
2,456,917 2.556 % 79 M $
Deep Track Capital LP
2.341 %
2,250,000 2.341 % 72 M $
Federated Global Investment Management Corp.
2.098 %
2,016,300 2.098 % 65 M $
Geode Capital Management LLC
2.053 %
1,973,269 2.053 % 63 M $

Company contact information

Intellia Therapeutics, Inc.

40 Erie Street Suite 130

02139, Cambridge

+857 285 6200

http://www.intelliatx.com
address Intellia Therapeutics, Inc.(NTLA)